Cipla Ltd. received USFDA approval for Nilotinib Capsules (50, 150, and 200 mg) on February 19, 2025, and plans to launch the product in FY 2025-26 for treating chronic myeloid leukemia.
AI Assistant
Cipla Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.